

China Sunsine Chemical Holdings Ltd

Aim for the long-term prosperity

SINGAPORE | MATERIALS | 2Q18 RESULTS

- 2Q18 revenue and net profit exceeded our full year expectation due to higher ASP and GPM, as well as a one-off tax credit granted.
- Uptrend in ASP and sales volume continued in 2Q18.
- GPM and NPM reached a record high in 2Q18.
- New capacity is expected to get approval by 3Q18.
- We revised down FY18e EPS to 22.9 SG cents (previously 23.3 SG cents) and FY19e EPS to 21.2 SG cents (previously 22.4 SG cents), due to higher R&D expenses and our expectation for upcoming product price to soften by 10.3% compared with the ASP of 1H18. We maintained our BUY recommendation with a lower target price of \$\$1.77 (previously \$1.97).

Results at a glance

(RMB mn)	2Q18	2Q17	YoY (%)	Comments
Revenue	881	656	34.2	Increase in overall ASP and sales volume
Gross profit	324	187	73.0	In line with the above
PBT	215	93	131.2	Increase in overhead costs and FX losses
PAT	240	75	221.7	In line with the above; a tax credit of
				RMB48mn granted

Source: Company, PSR

Positives

+ Uptrend in ASP and sales volume continued in 2Q18: In 2Q18, the total sales volume grew 8.7% YoY to 37.6k tonnes, due to higher production of insoluble sulphur and antioxidant. Meanwhile, overall ASP was still enjoying an upswing, touching RMB23.3k/tonne in 2Q18 (+25.8% YoY) (breakdowns are shown below):

Sales volume

(mn tonnes)	2Q18	2Q17	YoY (%)	1Q18	QoQ (%)
Accelerators	21,563	21,334	1.1	19,907	8.3
Insoluble Sulphur	6,672	4,913	35.8	6,212	7.4
Anti-oxidant	8,986	7,893	13.8	10,353	-13.2

Average selling price

(RMB/tonne)	2Q18	2Q17	YoY (%)	1Q18	QoQ (%)
Accelerators	29,486	21,698	35.9	29,387	0.3
Insoluble Sulphur	11,706	10,625	10.2	11,719	-0.1
Anti-oxidant	17,182	16,432	4.6	17,995	-4.5

Source: Company PSR

+ GPM and NPM reached a record high in 2Q18: The respective GPM and NPM were reported at 36.7% and 27.2% in 2Q18 (2Q17: 28.5% and 11.4%; 1Q18: 34.9% and 17.4%). Excluding the one-off tax credit of RMB48mn, the 2Q18 NPM was 21.8%. The significant improvements of margins were attributed to the growth of ASP outpaced that of raw material costs resulting from the tight supply within the market.

Negatives

- New capacity is expected to get approval by 3Q18: The trial run of the respective 10k-tonne newly-added capacity of accelerator TBBS and insoluble sulphur plant will be postponed to 3Q18. Hence, both plants could commence a full operation by 4Q18.



13 August 2018

BUY (Maintained)

TOTAL RETURN	47.2%
TARGET PRICE	SGD 1.770
FORECAST DIV	SGD 0.040
CLOSING PRICE	SGD 1.230

COMPANY DATA

Bloomberg Code:	CSSC SP
O/S SHARES (MN):	492
MARKET CAP (USD mn / SGD mn):	441/605
52 - WK HI/LO (SGD) :	1.65 / 0.77
3M Average Daily T/O (mn):	0.92

MAJOR SHAREHOLDERS (%)

SUCCESS MORE GROUP	59.7%
CHOON KONG KOH	0.9%
CHENG QIU XU	0.6%

PRICE PERFORMANCE (%)

	1M T H	3 M T H	1Y R
COMPANY	(3.7)	(15.1)	50.7
STIRETURN	5.1	(5.0)	3.8

RICE VS. STI



Source: Bloomberg, PSR

KEY FINANCIALS

Y/E Dec, RMB mn	FY16	FY 17	FY 18 e	FY 19 e
Revenue	2,037	2,738	3,277	3,488
Gross profit	540	788	1,081	1,099
PAT	222	341	547	511
P/E (x)	5.0	8.3	5.4	5.8
P/B (x)	8.0	1.6	1.3	1.1
ROE (%)	16%	20%	24%	19%
ROA (%)	13%	16%	20%	16%

Source: PSR

VALUATION METHOD

FCFE (Cost of Equity: 8.0%; Terminal g: 1.0%)

Chen Guangzhi (+65 6212 1859) chengz@phillip.com.sg

Page | 1 | PHILLIP SECURITIES RESEARCH (SINGAPORE)

MCI (P) 074/10/2017 Ref. No.: SG2018 0199




Outlook

CSSC achieved stellar performance in 2Q/1H18 due mainly to the shortage of rubber chemicals. Hence, ASP maintained at an elevated level. On the other hand, aniline price has been trending down due to more supply entering the market. Moving forward, we believe the supply shortage will be relieved as new capacities start to enter the market, together with more supply of aniline due to exporters partially shift US exports back to the domestic market. As a result, ASP correction could start in 3Q18. In 2H18, we expect CSSC to maintain GPM at more than 30%. We expect CSSC to deliver healthy performance for the next two quarters.

The room for growth will come from the new capacity which can help maintain performance and offset the softer chemical prices. Besides, "Battle for a Blue Sky" could be a short-term negative impact but a long-term beneficial driver. More environmental inspections will cause temporary disruption on operation in the industry, but it will gradually phase out uncompetitive and unperformed manufacturers. Therefore, CSSC will consolidate its market position as a leading supplier.

Figure 2: Price spread (accelerator/antioxidant and aniline) started to narrow



Source: CEIC, PSR

Maintain BUY with a lower TP of S\$1.77

We revised down FY18e EPS to 22.9 SG cents (previously 23.3 SG cents) and FY19e EPS to 21.2 SG cents (previously 22.4 SG cents), due to higher R&D expenses and our expectation for upcoming product price to soften by 11.1% compared with the ASP of 1H18. We maintained our BUY recommendation with a lower target price of S\$1.77 (previously S1.97).

Y/E, RMB mn	FY18e	FY19e	FY20e
Net income	547	511	490
Net capex	120	140	110
Chang in net WC	111	201	73
Change in borrowing	-	-	-
FCFE	316	170	307
Beta	0.99		
Required rate of return	8.0%		
Growth	1.0%		
FX (SGD/RMB)	4.85		
TP (SGD)	1.77		

Source: PSR

Battle for a Blue Sky: A three-year action plan to win the blue sky defense war announced by the central government in China. The plan aims to clean the nations' air. The authorities expect that within two years, total emissions of sulfur dioxide and nitrogen oxide will decrease more than 15% compared with 2015 levels. They also say PM2.5 will drop by more than 18%. Meanwhile, cities will enjoy "good" quality air days for about 80% of the year.



Financials

Income Statement

Y/E Dec, RMB mn	FY15	FY16	FY17	FY18e	FY19e
Revenue	1,859	2,037	2,738	3,277	3,488
COGS	(1,367)	(1,497)	(1,950)	(2,195)	(2,390)
Gross profit	492	540	788	1,081	1,099
EBITDA	392	410	567	705	724
Depreciation & Amortisation	94	96	90	96	101
EBIT	298	314	477	609	623
Net Finance (Expense)/Inc	(10)	(4)	-	-	-
PBT	288	310	477	609	623
Taxation	(92)	(88)	(136)	(62)	(112)
PAT	195	222	341	547	511

Per share data

1 Ci Silai C data					
Y/E Dec	FY15	FY16	FY17	FY18e	FY19e
EPS (RMB cents)	41.9	47.7	69.4	111.3	103.9
EPS (SG cents)	9.3	10.0	14.8	22.9	21.2
DPS (SG cents)	1.5	1.5	3.0	4.0	3.5
BVPS (RMB)	2.5	2.9	3.5	4.6	5.4
BVPS (SGD)	0.6	0.6	0.8	0.9	1.1

Cash Flow

Y/E Dec, RMB mn	FY15	FY16	FY17	FY18e	FY19e
CFO					
PBT	288	310	477	609	623
Adjustments	102	103	92	79	105
WC changes	133	(124)	(83)	(111)	(201)
Cash generated from ops	523	288	486	576	527
Others	(93)	(85)	(100)	(62)	(112)
Cashflow from ops	430	203	387	515	415
CFI					
CAPEX, net	(50.8)	(82.0)	(208.9)	(120.0)	(140.0)
Others	1.2	2.4	3.7	2.2	2.3
Cashflow from investments	(50)	(80)	(205)	(118)	(138)
CFF					
Loans, net of repayments	(120)	(148)	-	-	-
Dividends	(32)	(33)	(47)	(59)	(95)
Others	(0)	(8)	96	-	-
Cashflow from financing	(152)	(189)	50	(59)	(95)
Net change in cash	229	(65)	231	339	182
Effects of exchange rate	(0)	-	(9)	-	-
Ending cash	340	274	496	834	1,016

Source: Company, Phillip Securities Research (Singapore) Estimates

Balance Sheet


Y/E Dec, RMB mn	FY15	FY16	FY17	FY18e	FY19e
ASSETS					
PP&E	563	549	662	694	734
Others	44	43	41	40	39
Total non-current assets	606	592	703	735	773
Cash	341	276	500	834	1,016
Inventories	142	145	212	303	405
Trade receivables	414	548	638	765	877
Others	83	82	75	85	94
Total current assets	979	1,051	1,425	1,987	2,392
Total Assets	1,586	1,642	2,128	2,722	3,166
LIABILITIES					
Trade payables	43	52	71	75	84
Borrowings	145	-	-	-	-
Others	223	229	314	404	409
Total current liabilities	411	281	385	479	493
Borrowings	-	-	-	-	-
Total non-current liabilities	-	-	-	-	-
Total Liabilities	411	281	385	479	493
Total Equity	1,175	1,362	1,742	2,243	2,673

Valuation Ratios

Valuation Ratios					
Y/E Dec	FY15	FY16	FY17	FY18e	FY19e
P/E (x)	3.9	5.0	8.3	5.4	5.8
P/B (x)	0.7	0.8	1.6	1.3	1.1
EV/EBITDA	1.5	2.1	4.3	3.0	2.7
Growth & Margins (%)					
Growth					
Revenue	-10%	10%	46%	37%	2%
Gross profit	-13%	10%	46%	37%	2%
EBIT	-7%	5%	52%	28%	2%
PAT	-11%	14%	54%	60%	-7%
Margins					
GP margin	26%	27%	29%	33%	32%
EBIT margin	16%	15%	17%	19%	18%
PAT margin	11%	11%	12%	17%	15%
Key Ratios					
ROE (%)	17%	16%	20%	24%	19%
ROA (%)	12%	13%	16%	20%	16%
Net Debt or (Net Cash)	(196)	(276)	(500)	(834)	(1,016)
Gearing (%)	9.1%	0.0%	0.0%	0.0%	0.0%







PSR Rating System		
Total Returns	Recommendation	Rating
> +20%	Buy	1
+5% to +20%	Accumulate	2
-5% to +5%	Neutral	3
-5% to -20%	Reduce	4
< -20%	Sell	5

Remarks

We do not base our recommendations entirely on the above quantitative return bands. We consider qualitative factors like (but not limited to) a stock's risk reward profile, market sentiment, recent rate of share price appreciation, presence or absence of stock price catalysts, and speculative undertones surrounding the stock, before making our final recommendation



Contact Information (Singapore Research Team)

Head of Research

Banking and Finance

Paul Chew - paulchewkl@phillip.com.sg

Tin Min Ying - tinmy@phillip.com.sg

Transport | REITs (Industrial)

Oil & Gas | Energy

Chen Guangzhi - chengz@phillip.com.sg

REITs (Commercial, Retail, Healthcare) | Property

Contact Information (Regional Member Companies)

MALAYSIA

Phillip Capital Management Sdn Bhd

B-3-6 Block B Level 3 Megan Avenue II,

No. 12, Jalan Yap Kwan Seng, 50450

Kuala Lumpur

Tel +603 2162 8841

Fax +603 2166 5099

Website: www.poems.com.my

Dehong Tan - tandh@phillip.com.sg

US Equity

Ho Kang Wei - hokw@phillip.com.sg

Marketing & Operations

Telco | Technology Alvin Chia - alvinchiawy@phillip.com.sg

Mohamed Amiruddin - amiruddin@phillip.com.sg

Technical Analysis

Jeremy Ng - jeremyngch@phillip.com.sg

China/HK Equity

Zheng Jieyuan – zhengjy@phillip.com.sg

SINGAPORE

REITs (Commercial, Retail, Healthcare) | Property

Richard Leow - richardleowwt@phillip.com.sg

Tara Wong - tarawongsj@phillip.com.sg

Phillip Securities Pte Ltd

Raffles City Tower 250, North Bridge Road #06-00 Singapore 179101 Tel +65 6533 6001 Fax +65 6535 6631

Website: www.poems.com.sg

JAPAN

Phillip Securities Japan, Ltd.

4-2 Nihonbashi Kabuto-cho Chuo-ku, Tokyo 103-0026 Tel +81-3 3666 2101 Fax +81-3 3666 6090

Website: www.phillip.co.jp

INDONESIA

PT Phillip Securities Indonesia

ANZ Tower Level 23B, Jl Jend Sudirman Kav 33A Jakarta 10220 - Indonesia Tel +62-21 5790 0800 Fax +62-21 5790 0809 Website: www.phillip.co.id

FRANCE

King & Shaxson Capital Limited

3rd Floor, 35 Rue de la Bienfaisance 75008 Paris France Tel +33-1 45633100

Fax +33-1 45636017 Website: www.kingandshaxson.com

THAILAND

Phillip Securities (Thailand) Public Co. Ltd

15th Floor, Vorawat Building, 849 Silom Road, Silom, Bangrak, Bangkok 10500 Thailand Tel +66-2 6351700 / 22680999 Fax +66-2 22680921 Website www.phillip.co.th

UNITED STATES

Phillip Capital Inc

141 W Jackson Blvd Ste 3050 The Chicago Board of Trade Building Chicago, IL 60604 USA Tel +1-312 356 9000 Fax +1-312 356 9005

Website: www.phillipusa.com

INDIA

PhillipCapital (India) Private Limited

No.1, 18th Floor, Urmi Estate 95, Ganpatrao Kadam Marg Lower Parel West, Mumbai 400-013 Maharashtra, India

Tel: +91-22-2300 2999 / Fax: +91-22-2300 2969 Website: www.phillipcapital.in

CAMBODIA Phillip Bank Plc

Ground Floor of B-Office Centre,#61-64, Norodom Blvd Corner Street 306, Sangkat Boeung Keng Kang 1, Khan Chamkamorn, Phnom Penh, Cambodia

Tel: 855 (0) 7796 6151/855 (0) 1620 0769 Website: www.phillipbank.com.kh

HONG KONG Phillip Securities (HK) Ltd

11/F United Centre 95 Queensway Hong Kong Tel +852 2277 6600 Fax +852 2868 5307

Websites: www.phillip.com.hk

CHINA

Phillip Financial Advisory (Shanghai) Co Ltd

No 550 Yan An East Road, Ocean Tower Unit 2318, Postal code 200001 Tel +86-21 5169 9200 Fax +86-21 6351 2940

Website: www.phillip.com.cn

UNITED KINGDOM

King & Shaxson Capital Limited

6th Floor, Candlewick House, 120 Cannon Street, London, EC4N 6AS Tel +44-20 7426 5950 Fax +44-20 7626 1757

Website: www.kingandshaxson.com

AUSTRALIA

Phillip Capital Limited

Level 10, 330 Collins Street Melbourne, Victoria 3000, Australia Tel +61-03 8633 9803 Fax +61-03 8633 9899

Website: www.phillipcapital.com.au

TURKEY

PhillipCapital Menkul Degerler

Dr. Cemil Bengü Cad. Hak Is Merkezi No. 2 Kat. 6A Caglayan 34403 Istanbul, Turkey Tel: 0212 296 84 84 Fax: 0212 233 69 29 Website: www.phillipcapital.com.tr

SRI LANKA

Asha Phillip Securities Limited

2nd Floor, Lakshmans Building, No. 321, Galle Road, Colombo 03, Sri Lanka Tel: (94) 11 2429 100 Fax: (94) 11 2429 199

Website: www.ashaphillip.net

DUBAI

Phillip Futures DMCC

Member of the Dubai Gold and Commodities Exchange (DGCX) Unit No 601, Plot No 58, White Crown Bldg, Sheikh Zayed Road, P.O.Box 212291 Dubai-UAF

Tel: +971-4-3325052 / Fax: + 971-4-3328895

CHINA SUNSINE CHEMICAL HOLDINGS LTD RESULTS



Important Information

This report is prepared and/or distributed by Phillip Securities Research Pte Ltd ("Phillip Securities Research"), which is a holder of a financial adviser's license under the Financial Advisers Act, Chapter 110 in Singapore.

By receiving or reading this report, you agree to be bound by the terms and limitations set out below. Any failure to comply with these terms and limitations may constitute a violation of law. This report has been provided to you for personal use only and shall not be reproduced, distributed or published by you in whole or in part, for any purpose. If you have received this report by mistake, please delete or destroy it, and notify the sender immediately.

The information and any analysis, forecasts, projections, expectations and opinions (collectively, the "Research") contained in this report has been obtained from public sources which Phillip Securities Research believes to be reliable. However, Phillip Securities Research does not make any representation or warranty, express or implied that such information or Research is accurate, complete or appropriate or should be relied upon as such. Any such information or Research contained in this report is subject to change, and Phillip Securities Research shall not have any responsibility to maintain or update the information or Research made available or to supply any corrections, updates or releases in connection therewith.

Any opinions, forecasts, assumptions, estimates, valuations and prices contained in this report are as of the date indicated and are subject to change at any time without prior notice. Past performance of any product referred to in this report is not indicative of future results.

This report does not constitute, and should not be used as a substitute for, tax, legal or investment advice. This report should not be relied upon exclusively or as authoritative, without further being subject to the recipient's own independent verification and exercise of judgment. The fact that this report has been made available constitutes neither a recommendation to enter into a particular transaction, nor a representation that any product described in this report is suitable or appropriate for the recipient. Recipients should be aware that many of the products, which may be described in this report involve significant risks and may not be suitable for all investors, and that any decision to enter into transactions involving such products should not be made, unless all such risks are understood and an independent determination has been made that such transactions would be appropriate. Any discussion of the risks contained herein with respect to any product should not be considered to be a disclosure of all risks or a complete discussion of such risks.

Nothing in this report shall be construed to be an offer or solicitation for the purchase or sale of any product. Any decision to purchase any product mentioned in this report should take into account existing public information, including any registered prospectus in respect of such product.

Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may provide an array of financial services to a large number of corporations in Singapore and worldwide, including but not limited to commercial / investment banking activities (including sponsorship, financial advisory or underwriting activities), brokerage or securities trading activities. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have participated in or invested in transactions with the issuer(s) of the securities mentioned in this report, and may have performed services for or solicited business from such issuers. Additionally, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have provided advice or investment services to such companies and investments or related investments, as may be mentioned in this report.

Phillip Securities Research or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report may, from time to time maintain a long or short position in securities referred to herein, or in related futures or options, purchase or sell, make a market in, or engage in any other transaction involving such securities, and earn brokerage or other compensation in respect of the foregoing. Investments will be denominated in various currencies including US dollars and Euro and thus will be subject to any fluctuation in exchange rates between US dollars and Euro or foreign currencies and the currency of your own jurisdiction. Such fluctuations may have an adverse effect on the value, price or income return of the investment.

To the extent permitted by law, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may at any time engage in any of the above activities as set out above or otherwise hold an interest, whether material or not, in respect of companies and investments or related investments, which may be mentioned in this report. Accordingly, information may be available to Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, which is not reflected in this report, and Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may, to the extent permitted by law, have acted upon or used the information prior to or immediately following its publication. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited its officers, directors, employees or persons involved in the issuance of this report, may have issued other material that is inconsistent with, or reach different conclusions from, the contents of this report.

The information, tools and material presented herein are not directed, intended for distribution to or use by, any person or entity in any jurisdiction or country where such distribution, publication, availability or use would be contrary to the applicable law or regulation or which would subject Phillip Securities Research to any registration or licensing or other requirement, or penalty for contravention of such requirements within such jurisdiction.

This report is intended for general circulation only and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. The products mentioned in this report may not be suitable for all investors and a person receiving or reading this report should seek advice from a professional and financial adviser regarding the legal, business, financial, tax and other aspects including the suitability of such products, taking into account the specific investment objectives, financial situation or particular needs of that person, before making a commitment to invest in any of such products.

This report is not intended for distribution, publication to or use by any person in any jurisdiction outside of Singapore or any other jurisdiction as Phillip Securities Research may determine in its absolute discretion.

IMPORTANT DISCLOSURES FOR INCLUDED RESEARCH ANALYSES OR REPORTS OF FOREIGN RESEARCH HOUSES

Where the report contains research analyses or reports from a foreign research house, please note:

- (i) recipients of the analyses or reports are to contact Phillip Securities Research (and not the relevant foreign research house) in Singapore at 250 North Bridge Road, #06-00 Raffles City Tower, Singapore 179101, telephone number +65 6533 6001, in respect of any matters arising from, or in connection with, the analyses or reports; and
 - (ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Singapore who is not an accredited investor, expert investor or institutional investor, Phillip Securities Research accepts legal responsibility for the contents of the analyses or reports.